Preeclampsia and gestational diabetes mellitus: Pre-conception origins?

Medical Hypotheses

Volumn 79, Issue 1, 2012, Pages 120-125

  Wen, S W ^a,b,c   Xie, R H ^a,b,d   Tan, H ^c   Walker, M C ^a,b   Smith, G N ^e   Retnakaran, R ^f,g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d HUAIHUA MEDICAL COLLEGE   (China)

^e QUEEN S UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FOLIC ACID; GLUCOSE; INSULIN SENSITIZING AGENT; METFORMIN;

ARTICLE; CARDIOVASCULAR RISK; CHINA; COHORT ANALYSIS; DISEASE PREDISPOSITION; EXTREMELY LOW BIRTH WEIGHT; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; NEURAL TUBE DEFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; RISK REDUCTION;

DIABETES, GESTATIONAL; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84861457042     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.019     Document Type: Article

References (95)

1. ACOG Practice Bulletin No. 33. Obstet Gynecol 2002;99:159-67.
2. Buchanan T.A., Xiang A.H. Gestational diabetes mellitus. J Clin Invest 2005, 115(3):485-491.
3. Retnakaran R. Glucose tolerance status in pregnancy: a window to the future risk of diabetes and cardiovascular disease in women. Curr Diabetes Rev 2009, 5(4):239-244.
4. King H. Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care 1998, 21:B9-B13.
5. Roberts J.M., Lain K.Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002, 23:359-372.
6. Sibai B.M. Hypertension in pregnancy. Obstet Gynecol Clin N Am 1992, 19:615-632.
7. Ness R.B., Hubel C.A. Risk for coronary artery disease and morbid preeclampsia: a commentary. Ann Epidemiol 2005, 15(9):726-733.
8. Roberts J.M. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998, 16(1):5-15.
9. Carpenter M.W. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007, 30(Suppl. 2):S246-S250.
10. Bo S., Valpreda S., Menato G., et al. Should we consider gestational diabetes a vascular risk factor?. Atherosclerosis 2007, 194(2):e72-e79.
11. Meyers-Seifer, Vohr B. Lipid levels in former gestational diabetic mothers. Diabetes Care 1996; 19:1351-1356.
12. Verma A., Boney C.M., Tucker R., Vohr B.R. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab 2002, 87(7):3227-3235.
13. Lauenborg J., Mathiesen H., Hansen T., et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 2005, 90(7):4004-4010.
14. Retnakaran R., Qi Y., Sermer M., Connelly P.W., Zinman B., Hanley A.J. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. J Clin Endocrinol Metab 2010, 95:670-677.
15. Retnakaran R., Qi Y., Connelly P.W., Sermer M., Hanley A.J., Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of LDL cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. J Clin Endocrinol Metab 2010, 95:4345-4353.
16. Shah B.R., Retnakaran R., Booth G.L. Increased risk of cardiovascular disease in young women following gestational diabetes. Diabetes Care 2008, 31(8):1668-1669.
17. Brown D.W., Dueker N., Jamieson D.J., Cole J.W., Wozniak M.A., Stern B.J., et al. Preeclampsia and the risk of ischemic stroke among young women: results from the Stroke Prevention in Young Women Study. Stroke 2006, 37(4):1055-1059.
18. Wilson B.J., Watson M.S., Prescott G.J., Sunderland S., Campbell D.M., Hannaford P., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003, 326(7394):845.
19. Forest J.C., Girouard J., Masse J., Moutquin J.M., Kharfi A., Ness R.B., et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005, 105(6):1373-1380.
20. MacIsaac R.J., Jerums G., Cooper M.E. New insights into the significance of microalbuminuria. Curr Opin Nephrol Hypertens 2004, 13(1):83-91.
21. Barker D.J.P. Fetal programming and public health 1999, 3-11. RCOG Press, London. P.M.S. O'Brien, T. Wheeler, D.J.P. Barker (Eds.).
22. Dekker G.A., Sibai B.M. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998, 179:1359-1375.
23. Meis P.J., Goldenberg R.L., Mercer B.M., et al. The preterm prediction study: risk factors for indicated preterm births. Am J Obstet Gynecol 1998, 178(3):562-567.
24. Peek M.J., Horvath J.S., Child A.G., Henderson-Smart D.J., Peat B., Gillin A. Maternal and neonatal outcome of patients classified according to the Australasian society for the study of hypertension in pregnancy consensus statement. Med J Aust 1995, 162:186-189.
25. Ales K.L., Frayer W., Hawks G., Auld P.M., Druzin M.L. Development and validation of a multivariate predictor of mortality in very low birth weight. J Clin Epidemiol 1988, 41:1095-1103.
26. Whitfield M.F., Grunau R.V., Holsti L. Extremely premature (≤800g) schoolchildren: multiple areas of hidden disability. Arch Dis Child Fetal Neonatal Ed 1997, 77:85F-90F.
27. Liu A., Wen S.W., Bottomly J., Walker M.C., Smith G. Utilization of health care services of pregnant women complicated by preeclampsia in ontario. Hypertens Pregnancy 2009, 28:76-84.
28. Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, White RR, Roddy M, Hladunewich M; Pre-Eclampsia New Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol 2009; 200(1):58.e1-8.
29. Podjarny E., Losonczy G., Baylis C. Animal models of preeclampsia. Semin Nephrol 2004, 24:596-606.
30. Roberts J.M., Sheer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 2004, 24(6):557-564.
31. Bellamy L., Casas J.P., Hingorani A.D., Williams D. Type 2 diabetes after gestational diabetes a systematic review and meta-analysis. Lancet 2009, 373:1773-1779.
32. Kim C., Newton K.M., Knopp R.H. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002, 25(10):1862-1868.
33. Retnakaran R., Shah B. Mild glucose intolerance in pregnancy and risk of cardiovascular disease in young women: population-based cohort study. CMAJ 2009, 181(6-7):371-376.
34. Pedersen J. Diabetes and pregnancy: blood sugar of newborn infants. PhD Thesis. Copenhagen: Danish Science Press; 1952.
35. Freinkel N. Banting lecture 1980: of pregnancy and progeny. Diabetes 1980, 29:1023-1035.
36. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358(19):1991-2002.
37. Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes Care 1998, 21:B19-B26.
38. Brackley K.J., Ramsay M.M., Broughton Pipkin F., Rubin P.C. A longitudinal study of maternal bloodflow in normal pregnancy and the puerperium: analysis of doppler waveforms using laplace transform techniques. Br J Obstet Gynaecol 1998, 105(1):68-77.
39. Salihu H.M., Weldeselasse H.E., Rao K., Marty P.J., Whiteman V.E. The impact of obesity on maternal morbidity and feto-infant outcomes among macrosomic infants. J Matern Fetal Neonatal Med 2011, 24(9):1088-1094.
40. Riskin-Mashiah S., Damti A., Younes G., Auslender R. First trimester fasting hyperglycemia as a predictor for the development of gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol 2010, 152(2):163-167.
41. Sacks D.A., Chen W., Wolde-Tsadik G., Buchanan T.A. Fasting plasma glucose test at the first prenatal visit as a screen for gestational diabetes. Obstet Gynecol 2003, 101(6):1197-1203.
42. Williams M.A., Qiu C., Muy-Rivera M., et al. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab 2004, 89:2306-2311.
43. Lain K.C., Daftary A.R., Ness R.B., Roberts J.M. First trimester adipocytokine concentrations and risk of developing gestational diabetes later in pregnancy. Clin Endocrinol 2008, 69:407-411.
44. Nanda S., Savvidou M., Syngelaki A., Akolekar R., Nicolaides K.H. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11-13weeks. Prenat Diagn 2011, 31(2):135-141.
45. Savvidou M., Nelson S.M., Makgoba M., Messow C.M., Sattar N., Nicolaides K. First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. Diabetes 2010, 59(12):3017-3022.
46. Wolf M., Sandler L., Hsu K., et al. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 2003, 26:819-824.
47. Qiu C., Sorensen T.K., Luthy D.A., et al. A prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol 2004, 18(5):377-384.
48. Wolf M., Sauk J., Shah A., Vossen Smirnakis K., Jimenez-Kimble R., Ecker J.L., et al. Inflammation and glucose intolerance. a prospective study of gestational diabetes mellitus. Diabetes Care 2004, 27(1):21-27.
49. Smirnakis KV, Plati A, Wolf M, Thadhani R, Ecker JL. Predicting gestational diabetes: choosing the optimal early serum marker. Am J Obstet Gynecol 2007; 196(4):410.e1-6.
50. Enquobahrie D.A., Williams M.A., Qiu C., Luthy D.A. Early pregnancy lipid concentrations and the risk of gestational diabetes mellitus. Diabetes Res Clin Pract 2005, 70:134-142.
51. Zhang C., Qiu C., Hu F.B., David R.M., van Dam R.M., Bralley A., et al. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PLoS One 2008, 3:e3753.
52. Tisi D.K., Burns D.H., Luskey G.W., Koski K.G. Fetal exposure to altered amniotic fluid glucose, insulin and insulin-like growth factor binding protein 1 occurs prior to screening for gestational diabetes mellitus. Diabetes Care 2011, 34:139-144.
53. Horvath K., Koch K., Jeitler K., Matyas E., Bender R., Bastian H., et al. Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. BMJ 2010, 340:c1395. 10.1136/bmj.c1395.
54. Crowther C.A., Hiller J.E., Moss J.R., McPhee A.J., Jeffries W.S., Robinson J.S. Australian carbohydrate intolerance study in pregnant women (ACHOIS) trial group. effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005, 352(24):2477-2486.
55. Landon M.B., Spong C.Y., Thom E., et al. Eunice kennedy shriver national institute of child health and human development maternal-fetal medicine units network. a multicenter randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009, 361(14):1339-1348.
56. Bouchard L., Thibault S., Guay S.P., Santure M., Monpetit A., St-Pierre J., et al. Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy. Diabetes Care 2010, 33(11):2436-2441.
57. Fernández-Morera J.L., Rodríguez-Rodero S., Menéndez-Torre E., Fraga M.F. The possible role of epigenetics in gestational diabetes: cause, consequence, or both. Obstet Gynecol Int 2010, 2010:605163.
58. Burguet A. Long-term outcome in children of mothers with gestational diabetes. Diabetes Metab 2010, 36:682-694.
59. Boney C.M., Verma A., Tucker R., Vohr B.R. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005, 115:e290-e296.
60. Franks P.W., Looker H.C., Kobes S., Touger L., Tataranni P.A., Hanson R.L., et al. Gestational glucose tolerance and risk of type 2 diabetes in young pima indian offspring. Diabetes 2006, 55(2):460-465.
61. Hillier T.A., Pedula K.L., Schmidt M.M., Mullen J.A., Charles M.A., Pettitt D.J. Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. Diabetes Care 2007, 30(9):2287-2292.
62. Vääräsmäki M., Pouta A., Elliot P., et al. Adolescent manifestations of metabolic syndrome among children born to women with gestational diabetes in a general-population birth cohort. Am J Epidemiol 2009, 169(10):1209-1215.
63. Krishnaveni G.V., Veena S.R., Hill J.C., Kehoe S., Karat S.C., Fall C.H. Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in indian children. Diabetes Care 2010, 33:402-404.
64. West N.A., Crume T.L., Maligie M.A., Dabelea D. Cardiovascular risk factors in children exposed to maternal diabetes in utero. Diabetologia 2011, 54:504-507.
65. Ward W.K., Johnston C.L., Beard J.C., Benedetti T.J., Halter J.B., Porte D. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985, 34(9):861-869.
66. Ryan E.A., Imes S., Liu D., et al. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 1995, 44:506-512.
67. Buchanan T.A. Pancreatic beta-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001, 86(3):989-993.
68. Retnakaran R., Qi Y., Sermer M., Connelly P.W., Hanley A.J., Zinman B. Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care 2008, 31:2026-2031.
69. Xiang A.H., Wang C., Peters R.K., Trigo E., Kjos S.L., Buchanan T.A. Coordinate changes in plasma glucose and pancreatic beta-cell function in latino women at high risk for type 2 diabetes. Diabetes 2006, 55(4):1074-1079.
70. Xiang A.H., Kawakubo M., Trigo E., Kjos S.L., Buchanan T.A. Declining beta-cell compensation for insulin resistance in hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care 2010, 33:396-401.
71. Xiang A.H., Kjos S.L., Takayanagi M., Trigo E., Buchanan T.A. Detailed physiologic characterization of the development of type 2 diabetes in hispanic women with prior gestational diabetes mellitus. Diabetes 2010, 59(10):2625-2630.
72. Retnakaran R., Qi Y., Sermer M., Connelly P.W., Hanley A.J., Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 2010, 33(8):1798-1804.
73. Retnakaran R., Qi Y., Ye C., Hanley A.J., Connelly P.W., Sermer M., et al. Hepatic insulin resistance is an early determinant of declining beta-cell function in the first year postpartum following glucose intolerance in pregnancy. Diabetes Care 2011, 34:2431-2434.
74. Winzer C., Wagner O., Festa A., et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004, 27(7):1721-1727.
75. Heitritter S.M., Solomon C.G., Mitchell G.F., Skali-Ounis N., Seely E.W. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005, 90(7):3983-3988.
76. Retnakaran R., Qi Y., Connelly P.W., Sermer M., Hanley A.J., Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta-cell dysfunction and fasting glycaemia. Diabetologia 2010, 53:268-276.
77. Catalano P.M., Huston L., Amini S.B., Kalhan S.C. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 1999, 180(4):903-916.
78. Gunderson E.P., Quesenberry C.P., Jacobs D.R., Feng J., Lewis C.E., Sidney S. Longitudinal study of prepregnancy cardiometabolic risk factors and subsequent risk of gestational diabetes mellitus: the CARDIA study. Am J Epidemiol 2010, 172(10):1131-1143.
79. Hedderson MM, Darbinian JA, Quesenberry CP, Ferrara A. Pregravid cardiometabolic risk profile and risk of gestational diabetes mellitus. Am J Obstet Gynecol 2011; 205(1):55.e1-7.
80. Veltman-Verhulst S.M., van Haeften T.W., Eijkemans M.J., de Valk H.W., Fauser B.C., Goverde A.J. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome. Hum Reprod 2010, 25(12):3123-3128.
81. Solomon C.G., Willett W.C., Carey V.J., Rich-Edwards J., Hunter D.J., Colditz G.A., et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 1997, 278(13):1078-1083.
82. Retnakaran R., Qi Y., Sermer M., Connelly P.W., Zinman B., Hanley A.J. Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. Clin Endocrinol 2009, 74(4):615-622.
83. Walker M.C., Smith G.N., Perkins S.L., Keely E.J., Garner P.R. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999, 180(3):660-664.
84. Cudmore M., Ahmad S., Al-Ani B., Fujisawa T., Coxall H., Chudasama K., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115(13):1789-1797.
85. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005.
86. Rana S., Karumanchi S.A., Levine R.J., Venkatesha S., Rauh-Hain J.A., Tamez H. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142.
87. Masuyama H., Nakatsukasa H., Takamoto N., Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007, 92(7):2672-2679.
88. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197(1):28.e1-6.
89. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12(6):642-649.
90. Bodnar L.M., Tang G., Ness R.B., Harger G., Roberts J.M. Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 2006, 164(5):470-477.
91. Hernandez-Diaz S., Werler M.M., Louik C., Mitchell A.A. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 2002, 156(9):806-812.
92. Wen SW, Chen XK, Rodger M, White RR, Yang Q, Smith GN, Sigal RJ, Perkins SL, Walker MC. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008;198:45.e1-7.
93. Canada Health. Nutrition for a healthy pregnancy: guideline for the Childbearing Years 1999, Minister of Public Works and Government Services, Ottawa. Canada.
94. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
95. Bobbert T., Rochlitz H., Wegewitz U., et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005, 54:2712-2719.